The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
Arvinas (NASDAQ:ARVN) Downgraded by Wedbush to Neutral
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcus Biosciences (RCUS – Research Report), ...
Zacks Investment Research on MSN23h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...